Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Lisa Nodzon, PhD, ARNP, AOCNP®
J Adv Pract Oncol 2021;12(suppl 1):20-22 |
© 2021 Harborside™
At the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, described the clinical implications of measuring minimal residual disease. Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, summarizes the key points for advanced practitioners.
For access to the full length article, please sign in